FDA approved tobramycin inhalation powder (TOBI Podhaler, Novartis) for the management of cystic fibrosis patients with Pseudomonas aeruginosa), a bacterium that causes lung infections.
Formulary Watch
Latest News
All News
Advertisement
Managed care and hospital decision-makers should consider that biological drugs are different from traditional drugs in terms of their complexity and there is potential for problems to arise when manufacturing is not strictly controlled. Furthermore, biological medicines are more difficult to characterize, produce, and reproduce than most traditional pharmaceuticals. This, in turn, can affect the medicine’s quality, safety, or efficacy, and can ultimately impact the reliability of supply, according to a presentation at the Hematology/Oncology Pharmacy Association’s annual conference in Los Angeles, in March.
Patients with type 2 diabetes achieved 6% weight loss with liraglutide 3 mg in a phase 3a obesity trial, according to Novo Nordisk.
The Academy of Managed Care Pharmacy (AMCP) is urging US House leaders to consider a number of proposals to rein in federal spending on healthcare without compromising the popular programs of Medicare and Medicaid.
Med Prep Consulting, Inc., a compounding pharmacy in Tinton Falls, NJ, is voluntarily recalling all lots of compounded products from its facility for fear of mold contamination, according to an FDA press release.
Diabetes drugs including exenatide (Byetta, Bydureon), liraglutide (Victoza), sitagliptin (Januvia, Janumet, Janumet XR, Juvisync), saxagliptin (Onglyza, Kombiglyze XR), alogliptin (Nesina, Kazano, Oseni), and linagliptin (Tradjenta, Jentadueto) are being evaluated by FDA for a potential link to pancreatitis and precancerous changes of the pancreas.
FDA approved (technetium Tc 99m tilmanocept (Lymphoseek, Navidea Biopharmaceuticals) Injection, a radioactive diagnostic imaging agent that helps doctors locate lymph nodes in patients with breast cancer or melanoma who are undergoing surgery to remove tumor-draining lymph nodes.
The use of extended-release niacin as an adjunct to statins does not reduce the risk of a heart attack or stroke in patients with pre-existing cardiovascular disease, according to researchers who led the HPS2-THRIVE study. The results of the study were reported at the American College of Cardiology conference in San Francisco on March 9.
After receiving input from more than 80 institutions across the United States, the American Society of Health Systems Pharmacists (ASHP) and the American Pharmacists Association (APhA) developed a new medication management care transition guide.
Advertisement
FDA is warning the public that azithromycin (Zithromax or Zmax; Pfizer) can cause abnormal changes in the electrical activity of the heart that may lead to potentially fatal cardiac arrhythmias.
Almost 98% of primary care physicians (PCPs), nurse practitioners, and pharmacists trust and recommend over-the-counter (OTC) medicines to their patients, according to a new survey released by the Consumer Healthcare Products Association (CHPA).
FDA has approved aripiprazole (Abilify Maintena, Otsuka and Lundbeck) for extended-release injectable suspension for the treatment of schizophrenia.
The first interim results in HCV/HIV co-infected patients from Boehringer Ingelheim’s ongoing hepatitis C (HCV) clinical trial program, HCVerso, have become available. These results, from the phase 3 trial STARTVerso 4, were presented recently at the 20th annual Conference on Retroviruses and Opportunistic Infections (CROI) in Atlanta.
The Centers for Disease Control and Prevention (CDC) reported that carbapenem-resistant enterobacteriaceae (CRE) has increased over the last decade and most cases of resistance are associated with healthcare exposures. To slow the dissemination of CRE infections, local and state health departments need to take the lead in prevention efforts, according to CDC’s Morbidity and Mortality Weekly Report released on March 5.
Centralized systems are likely to be the most efficient way to increase colorectal cancer screening, according to a trial published in the March 5 Annals of Internal Medicine.
FDA voted 2-12 against approval for an investigational, oral, twice-daily formulation of gabapentin (Sefelsa, Depomed) to treat moderate to severe vasomotor symptoms due to menopause.
FDA has issued a second complete response letter regarding a supplemental New Drug Application (sNDA) for rivaroxaban (Xarelto, Janssen) for the reduction of the risk of cardiovascular events in patients with acute coronary syndrome (ACS).
A new study led by a researcher at the Perelman School of Medicine at the University of Pennsylvania adds support to current medical recommendations stating that screening colonoscopy substantially reduces an average-risk adult’s likelihood of being diagnosed with advanced colorectal cancer (CRC) in either the right or left side of the colon.
The 2012/2013 seasonal influenza vaccine is moderately effective at preventing medically attended influenza. However, some vaccinated people may still become infected, so clinicians should use antivirals as recommended by CDC regardless of vaccination status, according to estimates published in Morbidity and Mortality Weekly Report (MMWR), February 22, 2013.
A recent study shows how much physician dispensing is costing states.
New molecular entity: Late last year FDA approved bedaquiline tablets for the treatment of pulmonary multi-drug-resistant tuberculosis (MDR-TB).
Allergy season is almost upon us and anti-histamine agents remain the top choice. However, researchers are looking for new medications to help patients with different needs.
A high calcium intake, from diet or the combination of diet and supplements may raise the rate of mortality, especially cardiovascular (CV) mortality.
Individuals with high cholesterol who stay on their statin medications over a 2-year period are healthier than comparable nonadherent individuals, but the overall cost of their care is slightly higher, according to a new study.
For patients with sexual disorders, there's been very little help, but a review of the pipeline indicates that help might soon be on the way.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
HS patients on biosimilar adalimumab lose response faster than those on the original drug
2
Global MS analysis links disability burden to rising economic strain
3
CMS negotiates a 70% discount for Ozempic and Wegovy
4
New drug class shows promise for geographic atrophy
5
